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One of the main pitfalls in EXAFS fitting is correlation among parameters, which can lead to unreli-
able fits. The use of theoretical Debye-Waller factors (DWs) is a promising way to reduce the number
of fitted parameters. When working with molecular dynamics, it is not only possible to evaluate DWs
from the statistical distributions issued from the trajectory but also to estimate the distribution an-
harmonicity, and to compute simulated average EXAFS spectra that can be fitted as experimental
ones, in order to assess the ability of EXAFS fitting to recover information on DWs, as well as
other structural and spectroscopical parameters. The case studied is oxaliplatin, a third generation
anticancer drug. The structural information and the simulated average spectra were derived from a
Car-Parrinello molecular dynamics (CP-MD) trajectory of a compound closely related to oxaliplatin.
We present the DWs issued from this simulation and their use, by taking their theoretical absolute
values (no DW fitted) or their ratios (one DW fitted). In this second approach, the fit of oxaliplatin
experimental spectra leads to DWs values very close to the theoretical ones. This shows that the
CP-MD trajectory provides a good representation of the distance distributions for oxaliplatin. Trans-
ferability of oxaliplatin DWs, for all relevant single and multiple scattering paths, to closely related
compounds is proven for the case of bis(oxalato)platinum(II) and bis(ethylene diamine)platinum(II).
© 2013 American Institute of Physics. [http://dx.doi.org/10.1063/1.4790516]
I. INTRODUCTION
Fitting EXAFS spectra has become an extremely useful
tool to solve the local structure around an absorbing atom for
many chemical systems in all matter states. Its main capa-
bility concerns systems lacking a long-range order and the
technique has proved to be particularly efficient to charac-
terize disordered coordination spheres. Structure determina-
tion by EXAFS is usually based on the standard EXAFS
equation (1) proposed by Sayers, Stern and Lytle,1 and the
fit of different structural parameters (distances Ri and Debye-
Waller factors σ i, in the assumption of harmonic distance dis-
tributions) for a given model (set of relevant scattering paths
i, with Ni equivalent scattering paths of effective amplitude
|fi(k, Ri)| and phase ψ i(k)),2





|fi(k, Ri)|e−2σ 2i k2e−2Ri/λ(k)
× sin(2kRi + 2∂1(k) + ψi(k)). (1)
A long recognized shortcoming in EXAFS fitting comes
from correlations among parameters, in particular those af-
fecting the amplitude: electronic reduction factor s02, num-
ber of equivalent paths Ni, effective scattering amplitude |fi(k,
Ri)|, Debye-Waller factor (DW) σ i, and mean free path λ(k).
When scattering paths with similar effective amplitudes and
phases have different distances, interference effects may in-
a)Author to whom correspondence should be addressed. Electronic mail:
provost@u-pec.fr.
duce strong correlations between distance and amplitude pa-
rameters. Then, the fitting of a large number of DWs may lead
to wrong structural solutions.3
In order to deal with a small number of independent
DWs, different authors have proposed the use of XAS-
external information, which has been either experimental4 or
theoretical. Thus, on the basis of geometrical relationships
and statistical uncertainties, Yokoyama et al.5 proposed fixed
values for ratios among the different DWs of related sin-
gle and multiple scattering paths. Several authors have un-
dertaken DW estimations based on the vibrational proper-
ties of the ensemble of neighbor atoms surrounding the ab-
sorber atom.6 Another way for undertaking the theoretical
estimation of DWs is based on the use of statistical struc-
tural distributions provided by computer simulations. Filip-
poni et al. include implicitly the DWs in the fit by means of
structural correlation functions.7 Another strategy is the ex-
plicit computation of cumulants of the corresponding geomet-
rical paths.8–10 Theoretical DW values have also been used
in approaches where quantum-mechanical optimization and
EXAFS fitting are coupled.11 However, to our knowledge, no
systematic evaluation of the impact of such theoretical DWs
on EXAFS fitting has been done.
For such an evaluation, the main difficulty comes from
the fact that other amplitude parameters are not always well
controlled, when dealing with experimental spectra, with dif-
ferent ways of computing phases and amplitudes12, 13 or in-
elastic loss parameters.13, 14 These amplitude parameters may
be a source of systematic errors in the fitting procedure when
working on experimental spectra.
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FIG. 1. Oxaliplatin, EDO-Pt, bis(oxalato)platinum(II), and bis-
(ethylenediamine)platinum(II) structures
EXAFS spectra, simulated from a molecular dynamics
(MD) trajectory, implicitly account for a statistical represen-
tation of the structure and its fluctuations, including anhar-
monicity behaviors. Then, uncertainties related to effective
amplitudes, inelastic loss parameters, and the electronic re-
duction factor can be minimized, and a thorough analysis of
the impact of DWs can be easily monitored. In this way, the
fitting of simulated spectrum provides a well-controlled in-
formation to develop new fitting strategies in EXAFS and to
assess their physical consistencies.
This approach is applied to oxaliplatin, a third genera-
tion anticancer drug of the cisplatin family.15 Oxaliplatin con-
tains a Pt(II) square planarly coordinated by two bidentate
ligands: oxalate and diaminocyclohexane (Fig. 1). Its main
pharmaceutical interest comes from the diaminocyclohexane
ligand,16 which is generally considered as inert.17, 18 The EX-
AFS spectrum of oxaliplatin as well as of several parent drugs
and their degradation products have been previously recorded
and analyzed by some of our group.19 In addition, we per-
formed a Car-Parrinello molecular dynamics (CP-MD) simu-
lation of ethyldiamineoxalatoplatinum(II) (EDO-Pt), a model
structure for oxaliplatin obtained by removal of the outer part
of the cyclohexane ring (Fig. 1), in water.20 Chemical studies
suggest that the cutting of the external part of diaminocyclo-
hexane does not affect the complex reactivity.17 The compar-
ison of theoretical XANES and EXAFS spectra calculated
either using a unique structure of oxaliplatin or EDO-Pt, or
averaging on a significant number of structures extracted from
the EDO-Pt trajectory, showed that EDO-Pt is a good spectro-
scopical model for oxaliplatin.21 The systematic errors, asso-
ciated with the distances determination in a standard EXAFS
fitting approach, were assessed by fitting both the simulated
and experimental spectra under the same conditions.
In this work, we extend our first study21 to the extraction
of information on DWs from the CP-MD trajectory and their
use in new approaches for accurate constrained EXAFS fit-
ting. For both single scattering and multiple scattering paths,
analysis of the distance distributions is used to support the
DWs estimation on the basis of the second cumulant, as pro-
posed by Merkling et al.10 Then they are used either through
their absolute values coming from the simulation or some of
their ratios. In the last case, an empirical DW σ 12 will be fit-
ted for the first coordination sphere single scattering paths,
and the rest of DWs are derived from σ 12 by applying ratios










In this way, the degree of transferability of theoretical ratios
to the experimental ones can be explored.
This paper deals with the use of MD DWs ratios (MDR)
or values (MDV) for the fit of experimental EXAFS spectra
of oxaliplatin. The comparison of these two DWs approaches
with other strategies on DWs constraints will be described
elsewhere. A step beyond is the transferability of these ratios
to other structurally related compounds, such that an enhance-
ment of their fitting could be achieved. The question has been
addressed, in this work, by undertaking the EXAFS fitting of
two compounds closely related to oxaliplatin, whose come
from the substitution of one of the platinum(II) bidentate
ligands to get the symmetric complexes: bis(oxalato) plati-
nate(II) and bis(ethylenediamine)platinum(II) (Fig. 1).
II. METHODOLOGY
A. Simulated spectra and MD-based Debye-Waller
factors
Simulated Pt LIII-edge EXAFS spectra of oxaliplatin
have been computed using a statistically meaningful num-
ber of snapshots (NMD) extracted from the CP-MD simula-
tion of EDO-Pt in aqueous solution as described in Ref. 20
(The system was formed by 1 EDO-Pt molecule plus 63 wa-
ter molecules. The simulation time was 32 ps—6 ps for ther-
malization and 26 ps for production—which needed around
400 h of computer time using 90 processors). For each snap-
shot M, an individual spectra χM(k) is computed, and the NMD
resulting spectra are averaged to yield the simulated EXAFS
spectrum χ (k):





The average EXAFS signal is obtained by the following
equation:9, 10












× sin(2kRMi + αMi(k)), (4)
where index i denotes a given scattering path. It is worth
noting that Eq. (4) differs from the conventional EXAFS
equation (1)1 in the fact that the exponential factor contain-
ing the DW has been replaced by a sum over a high num-
ber of MD structural arrangements (snapshots) which ac-
count for the thermal and structural disorder. This change
has fundamental implications because the need of a model or
a reference structure disappears when a simulated spectrum
is computed.22 In this study, a NMD value of 250 has been
used. Snapshots were extracted from the CP-MD simulation
of EDO-Pt in water already published. A higher number of
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snapshots (500) was used to check that no observable changes
appear into the simulated spectrum.
EXAFS calculations were performed with the FEFF8
code (version 8.4).23 The Hedin-Lundqvist exchange-
correlation potential was used to compute the electron den-
sity distribution within a self-consistent-field (SCF) approach.
Hydrogen atoms were included in the SCF procedure to com-
pute the potential, but they were not included as backscatter-
ers. In the simulated EXAFS spectra, the only parameter not
derived from computation was the amplitude reduction func-
tion, s02, that was set up to 0.94 in order to match the first peak
height of the experimental and simulated Fourier transform
(FT) of EXAFS spectra. A similar strategy to obtain simulated
EXAFS and XANES spectra of different ions in solution has
been successfully applied in previous works.9, 10, 22, 24 In this
work, the solvation structure has not been included, neither in
the computation of simulated spectra nor in the fitting proce-
dure, because its contribution is really small to the EXAFS
function. (CP-MD simulations show that the first shell of wa-
ter molecules is at a 4.14 Å distance from platinum20, 21; refer
also to Sec. II C).
The MD-based Debye-Waller factors were computed on
the basis of the distribution of intramolecular distances, as
proposed by several authors:8, 9
σ 2i = 〈(Ri − Ri)2〉 (5)
To this aim, a large number of snapshots (ca. 25 000) were
used. The calculation of DWs on the sole basis of the second
cumulant is well supported by Gaussian-like distributions of
distances in EDO-Pt, as shown in Sec. III A.
B. Experimental spectra
Oxaliplatin was obtained from different Sanofi pharma-
ceutical preparations: powder (excipient monohydrate lac-
tose; OxaliPt-sol, OxaliPt-liq1), used to prepare pellets or di-
luted in pure water to get a 10 mg/ml (25 mM) solution, or
solution 5 mg/ml ready for injection (solvent: water, no excip-
ient; OxaliPt-liq2, OxaliPt-liq3). In these aqueous solutions,
oxaliplatin is known to be very stable. Potassium bis(oxalato)
platinate(II) and bis(ethylenediamine) platinum(II) chloride
were purchased from Sigma Aldrich and prepared as pel-
lets. For all samples, the total absorbance after edge was less
than 1.0, with an absorbance jump of 0.5 for solids and 0.1–
0.15 for liquids. Pt-LIII-edge XAS spectra were recorded in
transmission mode during different runs, at LURE (Orsay,
France, EXAFS13 station of the DCI storage ring, Si(111)
double crystal monochromator, resolution E/E > 2 × 10−4)
for the solid (OxaliPt-sol), and at ELETTRA (Trieste, Italy,
BL11.1 station, Si(111) double crystal monochromator, reso-
lution E/E ∼ 10−4; OxaliPt-liq1), ESRF (Grenoble, France,
BM29 station, Si(311) double crystal monochromator, res-
olution E/E ∼ 1.5 × 10−4; OxaliPt-liq2), and SOLEIL
(Saint Aubin, France, SAMBA station, Si(111) double crystal
monochromator, resolution 1.7 E/E ∼ 10−4; OxaliPt-liq3)
for liquids, with an energy-range of 11 260–13 000 eV. Har-
monic rejection was achieved with a total reflection mirror
at Elettra and SOLEIL, using a slight detuning of the double
crystal monochromator at LURE (the flux at the third har-
monic was very low) and a 50% detuning of both crystals at
ESRF. All spectra were recorded at room temperature.
The spectra were extracted using standard
procedures13, 25 available in the program Cherokee (MAX),26
including spline smoothing atomic absorption determination,
energy-dependent normalization and fast Fourier transform
(E0 taken at the inflection point 11568 eV, FT range 2.3–16
Å−1). Each spectrum was recorded three times in order to
estimate the average and the experimental errors. The noise
was suppressed by filtering all signals above 5 Å.
C. Fitting procedure
Both simulated and experimental spectra were fitted us-
ing the same procedure. The fits were performed on the
2.3–16.0 Å−1 k-range with a k3-weighting. Effective phases
and amplitudes were calculated with FEFF823 on the ba-
sis of the different model structures: the EDO-Pt gas-phase
structure20 optimized quantum-mechanically, and, the ox-
aliplatin, bis(oxalato) platinate(II), and bis(ethylenediamine)
platinum(II) crystallographic structures.27, 28 The backscatter-
ing potentials were derived either from a SCF electronic den-
sity of the system (SCF) or using the atomic tabulated data
(noSCF). All fits use FEFF8 mean free paths, except for some
of the fits presented in Table IV(b), where the empirical mini-
mal curve (	 = 0.7, η = 3.0) was applied.13 The introduction
of a second mean free path model at this step of the study
aimed to check that our results were not influenced by the
choice of the mean free path model. Finally, s02 was fitted.
The fitting procedure includes two steps:
(1) Fit of the first coordination sphere, on the basis of a 4 Pt-
(N/O) shell: In this step, first coordination sphere filtered
spectra (0–2.2 Å range) are used. The energy correction
E, a unique distance R, s02, and a unique DW (σ 2) are
fitted.
(2) Fitting of the whole signal on the basis of a 7-shell model
previously tested on oxaliplatin:21 single scattering (SS)
paths in the first coordination sphere (paths 1a and 1b
considered as a unique contribution 1, see Fig. 2); SS
paths in the second coordination sphere (2–3); main SS
and multiple scattering (MS) paths of oxalate (4–6); MS
through platinum (7). Path selection was done according
to the paths amplitudes in the fitting k-range. The am-
plitude of the 3-legs Pt-N-O scattering path (8) is much
lower than that of the 4-legs scattering path involving the
same atoms (7) one in the 2.3–16 Å−1 k-range with a k3-
weighting. The remaining scattering paths have low con-
tributions to the EXAFS signal. In our previous study,21
we have shown that the solvation structure could hardly
be detected, only on the simulated spectrum, at a dis-
tance of 4.14 Å from platinum. The solvent contribu-
tion is too low to be detected on our experimental struc-
tures. A new set of experimental data for oxaliplatin in
solid and solution recorded on the same beamline under
equivalent conditions should be carried out to undertake
this question. Thus the water molecules are neglected in
this study. In the second step, E is set to the value ex-
tracted from the first step.
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FIG. 2. Scattering path numbering. Cox and Ced are the carbon atoms be-
longing to the oxalate and ethylenediamine ligands, respectively. EXAFS fits
include signals for paths 1–7 only.
Due to implicit correlations among the different paths, in
this second step, constraints were applied on distances, in or-
der to limit the number of fitted distances to 3. For EDO-Pt,
oxaliplatin and bis(oxalato) platinate(II), a common distance
is employed for scattering paths 4–5–6 of oxalate (R4 = R5
= R6), and a distance shift of R47 = R7 − R4 = 0.1 Å is ap-
plied between oxalate scattering paths and MS through plat-
inum 7. For EDO-Pt and oxaliplatin, a second distance shift
of R23 = R3 − R2 = 0.1 Å is used, between the two Pt-C
SS paths. These distance shifts values are based on EDO-Pt
optimized structure (R23 = 0.14 Å and R47 = 0.11 Å)20
and oxaliplatin crystallographic structure (R23 = 0.13 Å and
R47 = 0.07 Å).27
CP-MD based DWs for EXAFS fitting have been tested
adopting two strategies (MDR and MDV options), which in-
troduce a different DW for each scattering path. In the MDV
case (MD Values), the DW values are obtained from the MD
trajectory according to Eq. (5) and fixed, i.e., none of the DWs
are fitted. The second strategy consists in fitting the DW for
SS within the first coordination sphere (σ 12), whereas the rest
of DWs are obtained from σ 12 according to the ratios ob-
served between the MD-DWs as expressed in Eq. (2). This
option is called MDR (MD ratios).
All the fits were performed using the RoundMidnight
code.26 The statistical errors (εi) on the average spectra and
error bars for the fitted parameters were evaluated as recom-
mended by the IXS Standard and Criteria Subcommittee.29
According to these recommendations, the goodness of fit or
quality factor is QF = χ2min/ν, where χ2min is the mini-
mum value of the statistical χ2 and ν = Nind − Npar is the
degree of freedom. Nind is the number of independent points
and Npar is the total number of fitted parameters. Since a k3-
weighting is used, the statistical χ2 in k-space is calculated
as proposed by Vlaic et al.30 In R-space, χ2 is calculated
according to Ref. 29. The mean experimental error 〈ε〉 is cal-
culated on kχ exp spectra by evaluating the point dispersion,
corrected by the Student statistics as recommended by the IXS
Standard and Criteria Subcommittee. In the fitting range, 〈ε〉
ranges between 0.011 and 0.027 for the experimental spectra.
For theoretical spectra, an error of the same order of mag-
nitude as for the experimental spectra: 〈ε〉 = 0.015 Å was
adopted.
III. RESULTS AND DISCUSSION
A. MD-based DW factors
Figure 3 shows the distance distributions (red lines) for
scattering paths 1–7, obtained from the CP-MD trajectory.
These distributions are nicely fitted by Gaussian functions
(black lines in Fig. 3), which supports the DW computation
as the second-order cumulant of an EDO-Pt scattering paths.
As long as we consider the sole EDO-Pt molecular structure,
no clear anharmonicity is observed. This is not the case for
scattering paths involving hydration water molecules.20 Such
a Gaussian behavior of intramolecular distances in EDO-Pt is
due to the strong bonding interactions between the Pt cation
and its ligands, what was already observed in the analysis of
the radial distribution functions for this compound.20
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FIG. 3. Distance distributions of the scattering paths 1–7 (red) and their fits
by a Gaussian function (black line).
 Reuse of AIP Publishing content is subject to the terms: https://publishing.aip.org/authors/rights-and-permissions. Downloaded to  IP:  150.214.182.116 On: Wed, 26 Oct
2016 13:20:47
084303-5 Provost et al. J. Chem. Phys. 138, 084303 (2013)
TABLE I. Average distances ( ¯RCP−MD) and MD-based DW factors
(σCP−MD2). Nleg is the number of legs of each path.
¯RCP−MD σCP−MD2 ¯RCP−MD σCP−MD2
Patha Nleg (Å) (Å2) Path Nleg (Å) (Å2)
1a 2 2.047 0.0024 1b 2 2.048 0.0024
2 2 2.826 0.0029 3 2 2.925 0.0041
4 2 4.032 0.0035 5 3 4.052 0.0033
6 4 4.071 0.0032 7 4 4.094 0.0044
8 3 4.091 0.0044 9 4 4.094 0.0095
10 4 4.095 0.0098 11 3 3.385 0.0029
12 3 3.409 0.0039 13 3 3.585 0.0062
aFor the path index, refer to Fig. 2.
Table I presents the average distances and DWs, com-
puted from the CP-MD simulation, for the scattering paths
defined in Fig. 2. Despite the different nature of the two biden-
tate ligands, oxalate and ethyldiamine, the two single scatter-
ing (SS) paths within the first coordination sphere (1a: Pt-
O and 1b: Pt-N) present almost the same average distance
as well as distance distribution. Distances obtained for the
two Pt-C SS paths (2–3) differ by 0.1 Å (RPt−Ced − RPt−Cox ).
This was already observed in the model structures, EDO-Pt
quantum-mechanically optimized20 and oxaliplatin crystallo-
graphic data.27 Furthermore, Pt-Ced distance distribution (3
in Fig. 3) is much broader than the Pt-Cox one (2 in Fig. 3),
(σ 23 )MD being 30% larger than (σ 22 )MDvalue.
At first sight, it could be expected a good correlation be-
tween the DW values and their corresponding path lengths:
the DW values for SS in the first coordination sphere (R ∼ 2
Å) should be the smallest ones, then DWs for SS in the second
coordination sphere (R ∼ 3 Å) should be somewhat larger, fol-
lowed by the triangular scattering paths (R ∼ 3.5 Å), whereas
the largest DWs values would correspond to paths with length
around 4 Å [oxalate SS and multiple scattering (MS), and
MS through Pt]. However, this is not the behavior observed
in Table I. The different degree of flexibility of oxalate and
ethylenediamine ligand is responsible for a different sequence
of values. Pt-Ced (3) DW appears to be closer to Pt-N-Pt-O
MS DW (7) than to that of Pt-Cox (2), while DWs associated
with oxalate scattering (4–6) are closer to Pt-Cox DW than to
Pt-N-Pt-O DW. In fact, the average DW for all Pt-C scattering
paths (both Pt-Cox and Pt-Ced paths: σP t−Cox/ed 2 = 0.0035 Å2)
is still slightly larger than the average DW factor of all oxalate
paths (paths 4–5–6: σox2 = 0.0033 Å2).
In the 1st coordination sphere, DWs for MS through plat-
inum (7–8) are almost twice those of SS DWs (1a–1b). In
addition, ratios between Pt-O-Pt-O (9) and Pt-O(1a) on one
hand, and Pt-N-Pt-N (10) and Pt-N (1b) on the other hand, are
close to 4. Such ratios agree with Yokoyama’s model for 1st
coordination sphere MS DW factors.5 However, Yokoyama’s
empirical ratios for triangular paths cannot be applied to
the system under study: the DW values obtained for the tri-
angular paths are rather different for Pt-O-O (11) (σP tOO2
= 0.0029 Å2), Pt-N-N (12) (σP tNN 2 = 0.0039Å2) and Pt-N-
O (13) (σP tNO2 = 0.0062 Å2). The values of paths 11 and 12
are respectively close to the Pt-Cox (2) and Pt-Ced (3) ones,
whereas the Pt-N-O (13) DW is twice that of the Pt-O-O one.
Thus the assignment of empirical ratios for triangular paths
should be done with a special care, particularly in the case
of bidentate ligands. For such scattering paths or for more
complex systems, the use of ratios derived from theoretical
approaches appears to be a more reliable strategy than the use
of empirical ones.
B. Fit of EDO-Pt simulated and oxaliplatin
experimental spectra
Figure 4 presents EDO-Pt simulated spectrum and the
different oxaliplatin experimental spectra recorded on liquid
and solid samples. Since this paper deals with the question of
DWs in EXAFS, an aim is to check to which point the theoret-
ical values can be validated by experiment, using oxaliplatin
experimental spectra. A first step is to check that EXAFS fit
FIG. 4. EDO-Pt simulated and oxaliplatin experimental spectra (a) and their
Fourier transform modulus (b).
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TABLE II. EXAFS fit of EDO-Pt.a
noSCF SCF
MDR MDV MDR MDV CP-MD
s02 1.24(7) 1.10(5) 0.95(3) 0.92(2)
σ 1
2 × 104b 36(5) 24 26(3) 24 24
R1 2.02(1) 2.02(1) 2.03(1) 2.03(1) 2.05(5)
R2 2.80(2) 2.80(2) 2.86(1) 2.86(1) 2.83(5)
R4 3.99(2) 4.00(2) 4.07(1) 4.07(1) 4.05(8)
QF 1.93 2.23 0.65 0.65
aError 〈ε〉 = 0.015.
bσ 1
2 values expressed in Å2, distances expressed in Å. Other distances derived from R2
and R4 using constraints described in Sec. II C.
of simulated spectra provides DW values close to theoretical
ones, before extracting information on DWs from experimen-
tal spectra, in a second step. However, experimental EXAFS
data may be perturbed by systematic errors, in particular those
related to the extraction procedure. This is the reason why we
include in this study different experimental spectra, recorded
in different synchrotron sources and independently studied, to
have an estimation of the error related to the extraction proce-
dure. Figure 4(b) shows that, despite a careful sample prepara-
tion and spectra extraction, non-negligible changes can be ob-
served in the Fourier transform main peak amplitude, which
may impact the fitted amplitude parameters.
Simulated spectra were generated using SCF based
phases and amplitudes. However, most EXAFS studies are
performed with noSCF phases and amplitudes. For this rea-
son, we tested MDR and MDV for both SCF and noSCF
phases and amplitudes, in order to check whether a refined
model of scattering potentials was necessary or not, in the
purpose of including CP-MD DWs in EXAFS fits.
For all spectra, good fits are obtained when using either
MDR or MDV whatever the choice applied for the determi-
nation of the effective scattering amplitudes (noSCF or SCF).
The quality factors are close to 1 or lower, and the fitted dis-
tances are in good agreement with the actual distances which
are average distances issued from the CP-MD trajectory for
EDO-Pt,20 or the crystallographic structure for oxaliplatin.27
Tables II and III present the fitted parameters obtained re-
TABLE III. EXAFS fit of OxaliPt-liq1.a
noSCF SCF
MDR MDV MDR MDV Cryst.
s02 1.07(7) 0.99(4) 0.80(5) 0.82(3)
σ 1
2 × 104 b 32(4) 24 22(4) 24
R1 2.00(1) 2.00(1) 2.02(1) 2.02(1) 2.04(2)
R2 2.76(2) 2.76(2) 2.85(2) 2.85(2) 2.77(7)
R4 3.97(2) 3.98(2) 4.04(2) 4.04(2) 4.00(2)
QF 1.54 1.64 1.35 1.32
aExperimental error 〈ε〉 = 0.015.
bσ 1
2 values expressed in Å2, distances expressed in Å. Other distances derived from R2
and R4 using constraints described in Sec. II C.
spectively for EDO-Pt simulated spectrum and one of the ex-
perimental spectra (OxaliPt-liq1, 10 mg/ml solution, excipi-
ent, Elettra; for other samples, see supplementary material31).
Figure 5 displays the corresponding experimental and theo-
retical EXAFS signals. When using SCF based phases and
amplitudes, the distances are slightly improved. However, the
quality factor reduction is mainly due to smaller systematic
errors at low k (Fig. 5). This is observed for all spectra.
When using noSCF phases and amplitudes, in most
cases, the quality factors are slightly larger for MDV than for
MDR. This is due to a lower number of free amplitude pa-
rameters to compensate systematic errors. The quality factors
ratios QFMDV/QFMDR are close to 1 for all spectra (lower than
1.16), except for OxaliPt-liq3 (1.42).31 The main difference
concerns the s02 values, which plays the role of a scale factor
and is highly correlated to σ 12. But all distances are identi-
cal within the error bars. When using SCF phases and am-
plitudes, the fits obtained for MDR and MDV can hardly be
distinguished, with quality factors ratios lower than 1.04 for
all spectra. Thus both MDR and MDV are good approaches
to limit the number of fitted parameters, for both noSCF and
SCF phases and amplitudes.
A systematic test on the performance of the use of DWs
in the fitting procedure is given in Table IV, which collects the
amplitude parameters (s02 and σ 12) and quality factors for all
fits with the MDR DWs choice (DWs ratios). Concerning the
fitted s02 values, a systematic change is observed. However,
FIG. 5. EXAFS fit of EDO-Pt (a) and (c) and OxaliPt-liq1 (b) and (d) using MDR.
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TABLE IV. s02, σ 12, and quality factors issued from the fit of the different spectra, with MDR conditions and
FEFF (a) or empirical (b) mean free path.
(a) noSCF SCF CP-MD
λFEFF 〈ε〉 s02 σ 12 × 104 (Å)2 QF s02 σ 12 × 104 (Å)2 QF σ 12 × 104 (Å)2
EDO-Pt 0.015 1.24(7) 36(5) 1.93 0.95(3) 26(3) 0.65 24
Oxali-liq1 0.015 1.07(6) 32(4) 1.54 0.80(5) 22(4) 1.35
Oxali-liq2 0.018 1.09(6) 28(4) 0.97 0.81(5) 18(4) 0.93
Oxali-liq3 0.011 1.05(4) 36(3) 1.18 0.79(4) 27(4) 1.30
Oxali-sol 0.027 1.10(9) 32(6) 0.76 0.85(4) 23(4) 0.28
(b) noSCF SCF CP-MD
λemp 〈ε〉 s02 σ 12 × 104 (Å)2 QF s02 σ 12 × 104 (Å)2 QF σ 12 × 104 (Å)2
EDO-Pt 0.015 1.22(7) 44(6) 2.00 0.82(4) 27(4) 1.30 24
Oxali-liq1 0.015 1.05(7) 39(6) 1.70 0.69(5) 23(5) 1.61
Oxali-liq2 0.018 1.06(6) 33(4) 1.11 0.70(5) 18(5) 1.17
Oxali-liq3 0.011 1.03(6) 43(5) 1.51 0.68(4) 27(4) 1.85
Oxali-sol 0.027 1.06(9) 38(7) 0.86 0.73(5) 24(5) 0.38
under the same amplitude, phase and mean free paths con-
ditions, s02 values for the four experimental spectra are equal
within the error bars. Thus, the observed significant variations
are due to well-defined systematic factors: (i) theoretical sim-
ulation or experimental spectra, (ii) SCF or noSCF phases
and amplitudes, and (iii) FEFF or empirical mean free path.
The difference between EDO-Pt simulated spectrum on the
one hand and oxaliplatin experimental spectra on the other
one can be easily explained by systematic errors induced by
the extraction procedure for the experimental spectra. The two
other s02 variation factors are discussed below.
For EDO-Pt simulated spectrum, the comparison be-
tween the fitted DWs and DWs issued from the CP-MD tra-
jectory allows us to find out whether the fitting conditions
succeed or not in providing the correct DWs values. When
using SCF phases and amplitudes, the fitted DWs are equal
to the MD values, within the error bars (σ 12 = 26(3) × 10−4
Å2). This is also true when introducing systematic errors on
the mean free path, by replacing FEFF mean free path (the
mean free path used in the simulated spectrum generation,
Table IV(a)) by an empirical one, based on the standard mini-
mum curve13 (	 = 0.7, η = 3.0 Table IV(b)). With SCF based
phases and amplitudes, the σ 12 values are not affected, the
systematic errors on mean free path are compensated by the
sole s02 parameter. Thus, using SCF phases and amplitudes, it
is possible to extract the right σ 12 value from the EXAFS fit,
when fitting both s02 and σ 12. When using noSCF phases and
amplitudes, the s02 and σ 12 values are more mean free path
dependent, and correlations result in an artificial increase of
both parameters which do not reflect the actual values (CP-
MD) anymore.
A similar behavior of both s02 and σ 12 is observed for
all experimental spectra. Nonreliable σ 12 values are obtained
when using noSCF phases and amplitudes, but reasonable
values are found when using SCF phases and amplitudes, on
the basis of the simulated spectrum study. With SCF, the σ 12
values are not affected by the choice of the mean free path
model, as for the simulated spectrum. The σ 12 values range
between 18(5) and 27(4) × 10−4 Å2, with an average value of
23 × 10−4 Å2, in good agreement with the theoretical value,
24 × 10−4 Å2. Thus, the results obtained from the experimen-
tal spectra suggest that CP-MD EDO-Pt in solution trajectory
gives a good description of the experimental distance distri-
butions for oxaliplatin in solution, at room temperature. A
deeper insight into the DW determination would imply to in-
clude the temperature dependence, what would lead to a set of
new experiments and computer simulations at different tem-
peratures. However, the aim of this study is to improve accu-
rate constrained EXAFS fitting.
C. Transferability to related compounds
Since the computation of a CP-MD trajectory for ev-
ery system under XAS study is not practical, it is impor-
tant to assess to which point these computed DWs are trans-
ferable to related compounds. The transferability of EDO-
Pt CP-MD DWs has been tested by using both MDR and
MDV strategies for the fit of bis(oxalato) platinate(II) and
bis(ethylenediamine) platinum(II). In these compounds, only
one of the two oxaliplatin ligands, oxalate or ethylenediamine,
is present. Thus, the 7-shell model used for EDO-Pt and oxali-
platin must be adapted: The fit of bis(oxalato) platinate(II) in-
cludes six of the seven scattering paths of oxaliplatin, with the
TABLE V. EXAFS fit of bis(oxalato) platinate(II).a
noSCF SCF
MDR MDV MDR MDV Cryst.
s02 1.10(5) 1.06(4) 0.86(4) 0.91(3)
σ 1
2 × 104 b 27(3) 24 19(3) 24
R1 1.99(1) 1.99(1) 2.00(1) 2.00(1) 2.00(1)
R2 2.77(1) 2.77(1) 2.79(1) 2.79(1) 2.78(1)
R4 3.97(1) 3.97(1) 4.00(1) 4.01(1) 3.97(2)
QF 1.76 1.74 1.53 1.64
aExperimental error 〈ε〉 = 0.012.
bσ 1
2 values expressed in Å2, distances expressed in Å. R5, R6, and R7 derived from R4
as described in Sec. II C.
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FIG. 6. Fit of bis(oxalato) platinate(II) (a) and (c) and bis(ethylenediamine)platinum(II) (b) and (d) using MDR.
constraints described in Sec. II C. Scattering path 3 (Pt-Ced)
is not included in the model. The fit of bis(ethylenediamine)
platinum(II) only includes paths 1 (1st coordination sphere
single scattering), 3 (Pt-Ced single scattering), and 7 (mul-
tiple scattering through platinum). The fitted parameters are
presented in Tables V and VI. Figure 6 shows the experimen-
tal and fitted EXAFS signals for MDR.
For both compounds, the use of Edo-Pt CP-MD based
DWs leads to good quality fits. The quality factors are close to
one, and the fitted distances are equal to the crystallographic
ones,28 within the error bars. MDR and MDV strategies give
close results. The fits differ only by their s02 and σ 12 values.
Thus, the two approaches present a similar performance in the
determination of the effective distances.
When fitting one DW, in the MDR strategy, we obtain
σ 1
2 values slightly lower than the average σ 12 observed for
oxaliplatin. However, taking into account the variability of
σ 1
2 observed among the different oxaliplatin experimental
spectra (Table IV), it is difficult to say how significant is the
difference in the σ 12 values obtained for bis(oxalato) platinate
(II) and bis(ethylenediamine) platinum(II).
The main result of this section is that the transferability
of EDO-Pt DWs is assessed for structure determination us-
ing MDR or MDV in EXAFS fit, for both SCF and noSCF
phases and amplitudes. In this work, the transferability can be
easily applied because we consider closely related complexes.
An extension of the method to more different and complex
TABLE VI. EXAFS fit of bis(ethylenediamine) platinum(II).a
noSCF SCF
MDR MDV MDR MDV Cryst.
s02 0.89(5) 0.84(4) 0.73(3) 0.78(3)
σ 1
2 × 104 b 29(4) 24 17(3) 24
R1 2.01(1) 2.01(1) 2.04(1) 2.04(1) 2.04(1)
R3 2.89(1) 2.89(1) 2.91(1) 2.91(1) 2.89(1)
R7 4.05(5) 4.05(5) 4.15(3) 4.15(3) 4.09(1)
QF 0.32 0.33 0.22 0.26
aExperimental error 〈ε〉 = 0.023.
bσ 1
2 values expressed in Å2, distances expressed in Å.
bioinorganic systems would imply a good knowledge of DWs
values, which can be system dependent. However, as soon as
it is possible to build a first reasonable structural model, the-
oretical DWs values can be determined, either by CP-MD or
by normal modes analysis, in order to constrain the fit of the
whole EXAFS signal.
IV. CONCLUDING REMARKS
Extraction of accurate information on the structural dis-
order in chemical systems from EXAFS fitting is difficult,
because of correlations between amplitude parameters, and
systematic errors affecting these amplitudes. This study has
shown that when working with simulated EXAFS spectra,
most sources of these systematic errors can be cancelled out.
This makes possible to assess the ability of EXAFS fitting to
recover information on DWs, and then to apply the informa-
tion gained on simulated spectra to experimental ones. The
case studied has been based on the use of a CP-MD simula-
tion of a good spectroscopical model of oxaliplatin in water,
EDO-Pt, that provided:
(i) a good knowledge of EDO-Pt configurational space,
average distances, and distance distributions, including
eventual anharmonicity;
(ii) the generation of average simulated spectra, which re-
flect the actual static and dynamic disorder, with the aid
of well-tested ab initio XAS codes, and that could be
fitted as experimental ones;
(iii) the precise knowledge of parameters affecting the pho-
toelectron behavior, in terms of potentials, scattering
paths phases and amplitudes, reduction factor and mean
free path, since the average spectra are simulated;
(iv) and, thus, the opportunity to check the impact of even-
tual systematic errors on these parameters.
It is not possible to fulfill all these points on the sole basis
of experimental spectra.
Distance distributions issued from the CP-MD trajectory
showed a negligible anharmonicity, for all significant scatter-
ing paths associated to the Pt complex. Thus, the estimation
of DWs as the second cumulant is reliable. The CP-MD DWs
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values were successfully used for the fit of oxaliplatin experi-
mental spectra, in two different approaches: using the CP-MD
DWs absolute values, or fitting a DW for one path and apply-
ing the theoretical DW ratios. The two approaches give satis-
factory results, from both the structural point of view and the
fit quality point of view.
Use of DWs ratios on simulated spectra showed that
EXAFS fitting could supply DWs information, provided that
phases and amplitudes were calculated by the self-consistent-
field approach. This result is not affected by the choice of the
mean free path model: the impact of error on this parameter
is corrected by a scale factor. Fit under the same conditions of
oxaliplatin experimental spectra showed that CP-MD gives a
good representation of the DWs for oxaliplatin in solution.
Fitting s02 was necessary in our study in order to check
that the σ 12 values were not affected by the other amplitude
parameters discussed in this paper. However, it is worth un-
derlining that it is not a standard recommended procedure,
because of correlations. When fitting unknown compounds
spectra, s02 should be fixed at the value obtained from a model
compound.
EDO-Pt CP-MD based DWs were useful for the
fit of bis(oxalato) platinate(II) and bis(ethylenediamine)
platinum(II), in both approaches, MD values or ratios, even
with a standard approach for phases and amplitudes. The
transferability is assessed for all relevant scattering paths,
including multiple scattering paths through platinum. Thus,
even if the use of the DWs values presented in this paper is
limited to specific systems, we believe that the strategy of in-
cluding theoretical DWs ratios to constrain the fits is a poten-
tially useful procedure what deserves further development.
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